Eagle’s Eye View: New ACC/AHA Dyslipidemia Guidelines Released
In this week’s View, Dr. Eagle looks at data from the STS/ACC TVT Registry on off label transcatheter valve interventions that demonstrate reduced residual tricuspid regurgitation (TR) and improved quality of life. He then explores the REVNOVATE-COMPLEX-PCI study that investigates the benefits of intravascular imaging guidance for five years. Finally, Dr. Eagle summarizes the ACC/AHA’s newly released clinical guidelines for managing dyslipidemia.
X Links:
- Kim Eagle, MD, MACC keaglemd
Clinical Topics: Acute Coronary Syndromes, Diabetes and Cardiometabolic Disease, Dyslipidemia, Invasive Cardiovascular Angiography and Intervention, Prevention, Atherosclerotic Disease (CAD/PAD), Hypertriglyceridemia, Lipid Metabolism, Nonstatins, Novel Agents, Primary Hyperlipidemia, Statins, Interventions and ACS, Interventions and Coronary Artery Disease, Interventions and Structural Heart Disease
Keywords: National Cardiovascular Data Registries, STS/ACC TVT Registry, Tricuspid Valve, Off-Label Use, Tricuspid Valve Insufficiency, Quality of Life, Registries, Acute Coronary Syndrome, Coronary Artery Disease, Percutaneous Coronary Intervention, PCSK9 protein, human, Blood Pressure, Calcium, Cholesterol, LDL, Cholesterol, LDL, Diabetes Mellitus, Type 2, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Proprotein Convertase 9, Secondary Prevention, Neoplasms, Hyperlipoproteinemia Type II, Renal Insufficiency, Chronic, Hypertriglyceridemia, Antibodies, Monoclonal, Primary Prevention, Apolipoproteins, Dyslipidemias, Myocardial Infarction, Triglycerides, Kidney, Stroke, EaglesEyeView
